賽升藥業(300485.SZ)：子公司君元藥業擬引資1500萬元 投後估值2.15億元
格隆匯12月24日丨賽升藥業(300485.SZ)公佈，公司召開第三屆董事會第十六次會議及第三屆監事會第十六次會議審議通過了《關於引入外部投資者向子公司增資的議案》。根據公司戰略發展需要，加速君元藥業建設，提升君元藥業核心管理層的治理水平，引入外部投資者向子公司君元藥業合計人民幣1500萬元增資，此次增資事項完成後，君元藥業註冊資本將增加至人民幣1290萬元。君元藥業主營中西藥製劑製造。
近日，公司作為丙方1及北京亦莊生物醫藥併購投資中心(有限合夥)作為丙方2(合稱“丙方”)、君元藥業作為乙方與瀋陽天邦藥業有限公司作為甲方1及王光作為甲方2(合稱“甲方”)簽署了《增資協議》。
甲方本輪投資金額為1500萬元，其中：甲方1的投資金額為350萬元，甲方2的投資金額為1150萬元。各方約定乙方投資前估值為2億元，投資後估值為2.15億元。增資後甲方將持有乙方6.98%的股權，其中：甲方的投資款中90萬元為新增註冊資本、溢價部分1410萬元列入乙方資本公積。此次增資完成後，乙方註冊資本金變更為1290萬元。
此外，對於後續增資的約定問題，各方一致同意，甲方做為乙方公司管理層有義務盡職履行管理職能，確保公司實現其經營目標，乙方發展經營完成以下里程碑事件，甲方有權以1元/股獲得乙方公司的股權激勵22萬股，對乙方進行增資取得乙方再次新增的22萬股股本，具體如下：
里程碑事件一：甲方負責在本次增資完成後的8-10個月內完成乙方基礎建設(是否完成的認定權在丙方)，甲方有權以1元/股對乙方進行增資取得乙方新增的13萬股(行權價格1元/股)；
里程碑事件二：甲方負責於2020年12月30日完成達到乙方生產經營狀態(是否達到的認定權在丙方)，甲方有權以1元/股對乙方進行增資取得乙方新增的9萬股(行權價格1元/股)。
甲方達成上述兩項里程碑事件並對乙方進行增資後，乙方將由丙方1、丙方2、甲方1、甲方2分別持股68.60%、22.87%、1.99%、6.54%。甲方將持有乙方8.53%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
